Diabetes and COVID-19: IDF perspective in the Western Pacific region
Date
2020Author
Hwang, Yerin
Khasag, Altaisaikhan
Jia, Weiping
Jenkins, Alicia
Huang, Chien-Ning
Yabe, Daisuke
Kim, Doo-Man
Kadowaki, Takashi
Lee, Moon-Kyu
Metadata
Show full item record
Documentos PDF
Imagenes y Videos
Abstract
The World Health Organization (WHO) declared a pandemic, the highest risk level in the
infectious disease alert phase, on 11 March 2020. In the Western Pacific Region (WPR),
192,016 confirmed cases with 7125 deaths had been reported as of 8 June 2020.
In people with diabetes COVID-19 can be more difficult to treat due to the wide fluctuations in blood glucose levels or presence of comorbidities such as diabetes complications,
including cardiovascular disease and renal damage, which are recognized risks for adverse
outcomes. National diabetes associations and governments have established guidelines for
subjects with diabetes in relation to COVID-19, and are trying to supply emergency and
their regularly required medical products for them.
The WPR is so large and composed of such diverse countries and COVID-19 situations, no
one conclusion or program applies. Instead we could see a diverse COVID-19 pandemic profile in the WPR, and several creative diagnostic and therapeutic measures undertaken. This
includes drive-through screening facilities, high-speed RT-PCR technologies, convalescent
patients’ plasma therapy, which potentially had some positive contributions in combatting
COVID-19 in the WPR as well as globally. Although the numbers of confirmed cases are currently decreasing in the region, the COVID-19 pandemic is not over, and many experts are
recommending to prepare measures for potential second or third waves of COVID-19.
Palabras clave
Diabetes; COVID-19Link to resource
https://doi.org/10.1016/j.diabres.2020.108278Collections
Comments
Respuesta Comentario Repositorio Expeditio
Gracias por tomarse el tiempo para darnos su opinión.